Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.

19 In the period from 31 March 2025 to 04 April 2025, a total of 175,000 shares were purchased under the share buyback program of RWE Aktiengesellschaft, the start of which was announced on 27 ...

In a report released on April 3, Ingo Becker from Kepler Capital maintained a Buy rating on RWE AG (0HA0 – Research Report), with a price target of €38.00. The company’s shares closed ...